RU2019120431A - Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ - Google Patents
Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ Download PDFInfo
- Publication number
- RU2019120431A RU2019120431A RU2019120431A RU2019120431A RU2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A RU 2019120431 A RU2019120431 A RU 2019120431A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- alkyl
- pharmaceutically acceptable
- methyl
- compound
- Prior art date
Links
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 title 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 19
- 238000000034 method Methods 0.000 claims 18
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 239000000651 prodrug Substances 0.000 claims 14
- 229940002612 prodrug Drugs 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 12
- 230000001771 impaired effect Effects 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 230000011664 signaling Effects 0.000 claims 12
- 230000001228 trophic effect Effects 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- -1 methylenedioxy Chemical group 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 125000001041 indolyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 210000004556 brain Anatomy 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102200143520 rs6265 Human genes 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000006289 Rett Syndrome Diseases 0.000 claims 2
- 208000034799 Tauopathies Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- QWKYIPKCLAUFCM-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylsulfinyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)C(F)(F)F)C=C1 QWKYIPKCLAUFCM-UHFFFAOYSA-N 0.000 claims 1
- OCINXEZVIIVXFU-UHFFFAOYSA-N 1-methyl-3-[3-methyl-4-[4-(trifluoromethylthio)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(SC(F)(F)F)C=C1 OCINXEZVIIVXFU-UHFFFAOYSA-N 0.000 claims 1
- 206010002027 Amyotrophy Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010066131 Congenital central hypoventilation syndrome Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000005890 Neuroma Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000007960 WAGR syndrome Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 208000036970 congenital 1 with or without Hirschsprung disease central hypoventilation syndrome Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000007659 motor function Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 206010069732 neurotrophic keratopathy Diseases 0.000 claims 1
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 210000002475 olfactory pathway Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000017423 tissue regeneration Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/30—Only oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651706-2 | 2016-12-21 | ||
| SE1651706 | 2016-12-21 | ||
| PCT/GB2017/053868 WO2018115891A1 (en) | 2016-12-21 | 2017-12-21 | Triazinetrione derivatives and their use as modulators of neurotrophin receptor and receptor tyrosine kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2019120431A true RU2019120431A (ru) | 2021-01-22 |
| RU2019120431A3 RU2019120431A3 (https=) | 2021-03-09 |
Family
ID=60923799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019120431A RU2019120431A (ru) | 2016-12-21 | 2017-12-21 | Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113910A1 (https=) |
| EP (1) | EP3558320A1 (https=) |
| JP (1) | JP2020502225A (https=) |
| KR (1) | KR20190098982A (https=) |
| CN (1) | CN110167558A (https=) |
| AU (1) | AU2017380583A1 (https=) |
| BR (1) | BR112019012709A2 (https=) |
| CA (1) | CA3046289A1 (https=) |
| IL (1) | IL267086A (https=) |
| MX (1) | MX2019007606A (https=) |
| RU (1) | RU2019120431A (https=) |
| WO (1) | WO2018115891A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816837C2 (ru) * | 2018-02-26 | 2024-04-05 | Алзекьюр Фарма Аб | Производные триазина для лечения заболеваний, связанных с нейротрофинами |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA52415A (fr) | 2018-02-26 | 2021-01-06 | AlzeCure Pharma AB | Dérivés de triazine pour le traitement de maladies associées à des neurotrophines |
| GB201810668D0 (en) | 2018-06-28 | 2018-08-15 | Stiftelsen Alzecure | New compounds |
| GB201912404D0 (en) * | 2019-08-29 | 2019-10-16 | AlzeCure Pharma AB | New compounds |
| CN113057957A (zh) * | 2021-03-30 | 2021-07-02 | 福建中医药大学 | 葛杜宁及其衍生物在制备抗氧化药物和/或化妆品及治疗类风湿性关节炎药物中的用途 |
| CN113893334A (zh) * | 2021-10-19 | 2022-01-07 | 内蒙古医科大学第二附属医院 | 基于cAMP/PKA-CREB-BDNF信号通路的七氟烷影响抑制剂及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2718799A1 (de) | 1977-04-27 | 1978-11-09 | Bayer Ag | 1-(4-phenoxy-phenyl)-1,3,5-triazin- derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und wachstumsfoerderer |
| KR101457027B1 (ko) * | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
| CN103180297A (zh) * | 2009-12-11 | 2013-06-26 | 基因密码公司 | 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法 |
-
2017
- 2017-12-21 JP JP2019534090A patent/JP2020502225A/ja active Pending
- 2017-12-21 CA CA3046289A patent/CA3046289A1/en not_active Abandoned
- 2017-12-21 AU AU2017380583A patent/AU2017380583A1/en not_active Abandoned
- 2017-12-21 US US16/471,923 patent/US20200113910A1/en not_active Abandoned
- 2017-12-21 EP EP17825283.9A patent/EP3558320A1/en not_active Withdrawn
- 2017-12-21 BR BR112019012709A patent/BR112019012709A2/pt not_active Application Discontinuation
- 2017-12-21 WO PCT/GB2017/053868 patent/WO2018115891A1/en not_active Ceased
- 2017-12-21 MX MX2019007606A patent/MX2019007606A/es unknown
- 2017-12-21 KR KR1020197018642A patent/KR20190098982A/ko not_active Ceased
- 2017-12-21 CN CN201780078675.XA patent/CN110167558A/zh active Pending
- 2017-12-21 RU RU2019120431A patent/RU2019120431A/ru not_active Application Discontinuation
-
2019
- 2019-06-04 IL IL267086A patent/IL267086A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2816837C2 (ru) * | 2018-02-26 | 2024-04-05 | Алзекьюр Фарма Аб | Производные триазина для лечения заболеваний, связанных с нейротрофинами |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110167558A (zh) | 2019-08-23 |
| IL267086A (en) | 2019-08-29 |
| BR112019012709A2 (pt) | 2019-11-26 |
| JP2020502225A (ja) | 2020-01-23 |
| RU2019120431A3 (https=) | 2021-03-09 |
| CA3046289A1 (en) | 2018-06-28 |
| WO2018115891A1 (en) | 2018-06-28 |
| EP3558320A1 (en) | 2019-10-30 |
| US20200113910A1 (en) | 2020-04-16 |
| MX2019007606A (es) | 2020-07-29 |
| AU2017380583A1 (en) | 2019-06-27 |
| KR20190098982A (ko) | 2019-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019120431A (ru) | Производные триазинтриона и их использование в качестве модуляторов нейротрофиновых рецепторов и рецепторов тирозинкиназ | |
| JP6134046B1 (ja) | 医療で使用されるインドール誘導体 | |
| CN103119031B (zh) | 取代酰胺化合物 | |
| JP7330510B2 (ja) | 非滲出型または萎縮型の黄斑変性にて以前に失われた視力を回復させるための医薬組成物 | |
| JP2022506111A5 (https=) | ||
| JP2020502225A5 (https=) | ||
| JP6837479B2 (ja) | 医薬化合物 | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| IL276624B2 (en) | Triazine derivatives for the treatment of neurotrophin-related diseases | |
| JP2016525104A5 (https=) | ||
| CN1237168A (zh) | 双环芳基甲酰胺及其治疗应用 | |
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| US7666857B2 (en) | 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3′-(1h-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline | |
| CA3089952A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| US11779565B2 (en) | Small organic molecules for use in the treatment of neuroinflammatory disorders | |
| JPWO2020092019A5 (https=) | ||
| CN115028679A (zh) | 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用 | |
| JP6928479B2 (ja) | 拒絶反応抑制剤 | |
| JPWO2021113665A5 (https=) | ||
| WO2025011661A1 (zh) | 整合酶抑制类的制剂及其制备方法 | |
| AU2017342240A1 (en) | Methods for treating ocular disease using inhibitors of CSF-1R | |
| KR101708764B1 (ko) | 중추신경계 질환의 치료 또는 예방용 약학 조성물 | |
| CN1125065C (zh) | 苯并[g]喹啉衍生物 | |
| JP6363192B2 (ja) | トリグリセリド、総コレステロール、及び低密度リポタンパク質の血中濃度を低減する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220422 |